An Aug. 2 circular from India's Central Drugs Standard Control Organization (CDSCO) has said that restrictions which specify that no investigator can conduct more than three trials at any given period of time are being "removed".
"It has been decided that the ethics committee (EC) after examining the risk and complexity involved in the trial being conducted/proposed shall decide about how many trials an investigator can...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?